Skip to main content

Table 3 MMP SNPs and development of COPD in Vlagtwedde/Vlaardingen (GOLD stage ≥ II)

From: Genetic variation in TIMP1 but not MMPs predict excess FEV1 decline in two general population-based cohorts

SNP

 

No COPD N (%)

COPD N (%)

P value

SNP

 

No COPD N (%)

COPD N (%)

P value

MMP1 G-1607GG

G

295 (26.4)

44 (24.7)

0.845

MMP9 rs6065912

TT

873 (77.0)

145 (80.1)

0.576

 

G&GG

565 (50.6)

94 (52.8)

  

TC

245 (21.6)

18 (33.2)

 
 

GG

257 (23.0)

40 (22.5)

  

CC

16 (1.4)

3 (1.7)

 

MMP2 C-1306T

CC

609 (52.8)

103 (55.4)

0.180

MMP9 rs8113877

TT

408 (35.8)

76 (40.6)

0.137

 

CT

466 (40.5)

65 (34.9)

  

TC

559 (49.0)

77 (41.2)

 
 

TT

77 (6.7)

18 (9.7)

  

CC

174 (15.2)

34 (18.2)

 

MMP12 Asn357Ser

AA

1054 (93.1)

171 (94.0)

0.673

MMP9 rs3918278

GG

1078 (94.7)

177 (96.7)

0.122

 

AG

78 (6.9)

11 (6.0)

  

GA

59 (5.2)

5 (2.7)

 
 

GG

0 (0)

0 (0)

  

AA

1 (0.1)

1 (0.6)

 

MMP12 A-82G

AA

812 (72.2)

130 (71.4)

0.831

     
 

AG

281 (25.0)

48 (26.4)

      
 

GG

32 (2.8)

4 (2.2)

     Â